Literature DB >> 28666118

RAS Proteins and Their Regulators in Human Disease.

Dhirendra K Simanshu1, Dwight V Nissley1, Frank McCormick2.   

Abstract

RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. The structural basis of the switch and many of the pathways that RAS controls are well known, but the precise mechanisms by which RAS proteins function are less clear. All RAS biology occurs in membranes: a precise understanding of RAS' interaction with membranes is essential to understand RAS action and to intervene in RAS-driven diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRAFT; KRAS; KRAS therapies; NF1; RAF1; RAS effectors; RAS in the membrane; RAS proteins; RAS-driven cancer; RASopathies

Mesh:

Substances:

Year:  2017        PMID: 28666118      PMCID: PMC5555610          DOI: 10.1016/j.cell.2017.06.009

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  154 in total

1.  Biochemical and Structural Insights into the Aminotransferase CrmG in Caerulomycin Biosynthesis.

Authors:  Yiguang Zhu; Jinxin Xu; Xiangui Mei; Zhan Feng; Liping Zhang; Qingbo Zhang; Guangtao Zhang; Weiming Zhu; Jinsong Liu; Changsheng Zhang
Journal:  ACS Chem Biol       Date:  2016-01-12       Impact factor: 5.100

Review 2.  HRAS and the Costello syndrome.

Authors:  K A Rauen
Journal:  Clin Genet       Date:  2007-02       Impact factor: 4.438

3.  Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras.

Authors:  M R Ahmadian; P Stege; K Scheffzek; A Wittinghofer
Journal:  Nat Struct Biol       Date:  1997-09

4.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Authors:  John C Hunter; Anuj Manandhar; Martin A Carrasco; Deepak Gurbani; Sudershan Gondi; Kenneth D Westover
Journal:  Mol Cancer Res       Date:  2015-06-02       Impact factor: 5.852

5.  The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction.

Authors:  Shobhna Kapoor; Katrin Weise; Mirko Erlkamp; Gemma Triola; Herbert Waldmann; Roland Winter
Journal:  Eur Biophys J       Date:  2012-08-01       Impact factor: 1.733

6.  Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.

Authors:  Sarah Naomi Olsen; Ania Wronski; Zafira Castaño; Benjamin Dake; Clare Malone; Thomas De Raedt; Miriam Enos; Yoko S DeRose; Wenhui Zhou; Stephanie Guerra; Massimo Loda; Alana Welm; Ann H Partridge; Sandra S McAllister; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Discov       Date:  2016-12-14       Impact factor: 39.397

7.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

8.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.

Authors:  D F Easton; M A Ponder; S M Huson; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

9.  A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.

Authors:  Karen W Gripp; Kimberly A Aldinger; James T Bennett; Laura Baker; Jessica Tusi; Nina Powell-Hamilton; Deborah Stabley; Katia Sol-Church; Andrew E Timms; William B Dobyns
Journal:  Am J Med Genet A       Date:  2016-06-05       Impact factor: 2.802

10.  Recurrent inactivating RASA2 mutations in melanoma.

Authors:  Rand Arafeh; Nouar Qutob; Rafi Emmanuel; Alona Keren-Paz; Jason Madore; Abdel Elkahloun; James S Wilmott; Jared J Gartner; Antonella Di Pizio; Sabina Winograd-Katz; Sivasish Sindiri; Ron Rotkopf; Ken Dutton-Regester; Peter Johansson; Antonia L Pritchard; Nicola Waddell; Victoria K Hill; Jimmy C Lin; Yael Hevroni; Steven A Rosenberg; Javed Khan; Shifra Ben-Dor; Masha Y Niv; Igor Ulitsky; Graham J Mann; Richard A Scolyer; Nicholas K Hayward; Yardena Samuels
Journal:  Nat Genet       Date:  2015-10-26       Impact factor: 38.330

View more
  448 in total

1.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

2.  KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.

Authors:  Dana Rabara; Timothy H Tran; Srisathiyanarayanan Dharmaiah; Robert M Stephens; Frank McCormick; Dhirendra K Simanshu; Matthew Holderfield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

3.  Ras and Rap Signal Bidirectional Synaptic Plasticity via Distinct Subcellular Microdomains.

Authors:  Lei Zhang; Peng Zhang; Guangfu Wang; Huaye Zhang; Yajun Zhang; Yilin Yu; Mingxu Zhang; Jian Xiao; Piero Crespo; Johannes W Hell; Li Lin; Richard L Huganir; J Julius Zhu
Journal:  Neuron       Date:  2018-04-26       Impact factor: 17.173

4.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

5.  The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?

Authors:  Wadie D Mahauad-Fernandez; Dean W Felsher
Journal:  Cancer Res       Date:  2020-07-30       Impact factor: 12.701

6.  Novel Mutations in RASGRP1 are Associated with Immunodeficiency, Immune Dysregulation, and EBV-Induced Lymphoma.

Authors:  Ido Somekh; Benjamin Marquardt; Yanshan Liu; Meino Rohlfs; Sebastian Hollizeck; Musa Karakukcu; Ekrem Unal; Ebru Yilmaz; Turkan Patiroglu; Murat Cansever; Shirly Frizinsky; Vicktoria Vishnvenska-Dai; Erez Rechavi; Tali Stauber; Amos J Simon; Atar Lev; Christoph Klein; Daniel Kotlarz; Raz Somech
Journal:  J Clin Immunol       Date:  2018-07-20       Impact factor: 8.317

7.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

8.  Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.

Authors:  Timothy F Day; Bhaskar V S Kallakury; Jeffrey S Ross; Olga Voronel; Shantashri Vaidya; Christine E Sheehan; Usha N Kasid
Journal:  Mol Cancer Res       Date:  2019-01-15       Impact factor: 5.852

9.  Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family.

Authors:  Francisco Llavero; Miriam Luque Montoro; Alazne Arrazola Sastre; David Fernández-Moreno; Hadriano M Lacerda; Luis A Parada; Alejandro Lucia; José L Zugaza
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

10.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.